<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC4247767/results/search/disease/results.xml">
  <result pre="of new drugs have been developed for HIV, HCV and" exact="influenza" post="virus, the optimal combinations of multiple drugs are incompletely"/>
  <result pre="drugs targeting HIV [5–13], HCV [14–18], HBV [19, 20] and" exact="influenza" post="virus [21, 22]. These studies have elucidated the key"/>
  <result pre="experience severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction," exact="peripheral neuropathy" post="and cardiovascular diseases (reviewed in [28]). By optimizing drug"/>
  <result pre="severe side effects such as lipodystrophy, hepatotoxicity, renal dysfunction, peripheral" exact="neuropathy" post="and cardiovascular diseases (reviewed in [28]). By optimizing drug"/>
  <result pre="we discuss how drug combination theory might be applied to" exact="cancer" post="chemotherapies and antiviral therapies. Combining mathematical models of viral"/>
  <result pre="usefulness of combining the Loewe additivity with mathematical modeling of" exact="hepatitis" post="C virus (HCV) replication. The aim is to optimize"/>
  <result pre="drug targets are decided. For example, using computational modeling of" exact="cancer" post="signaling networks and animal experiments, Kirouac et al.[46] identified"/>
  <result pre="the optimal inhibitor combination for suppressing the growth of ERBB2-amplified" exact="breast cancer." post="They adopted Bliss independence as a synergy criterion. Supplementing"/>
  <result pre="a biological system. The above research potentially benefits not only" exact="cancer" post="chemotherapy, but also antiviral therapy development. For instance, Owens"/>
  <result pre="interferon-alpha therapyScience199828210310710.1126/science.282.5386.1039756471 16.DixitNMLayden-AlmerJELaydenTJPerelsonASModelling how ribavirin improves interferon response rates in" exact="hepatitis" post="C virus infectionNature200443292292410.1038/nature0315315602565 17.DahariHRibeiroRMPerelsonASTriphasic decline of hepatitis C virus"/>
  <result pre="response rates in hepatitis C virus infectionNature200443292292410.1038/nature0315315602565 17.DahariHRibeiroRMPerelsonASTriphasic decline of" exact="hepatitis" post="C virus RNA during antiviral therapyHepatology200746162110.1002/hep.2165717596864 18.DahariHSainzBPerelsonASUprichardSLModeling subgenomic hepatitis"/>
  <result pre="of hepatitis C virus RNA during antiviral therapyHepatology200746162110.1002/hep.2165717596864 18.DahariHSainzBPerelsonASUprichardSLModeling subgenomic" exact="hepatitis" post="C virus RNA kinetics during treatment with alpha interferonJ"/>
  <result pre="RNA kinetics during treatment with alpha interferonJ Virol2009836383639010.1128/JVI.02612-0819369346 19.LewinSRRibeiroRMWaltersTLauGKBowdenSLocarniniSPerelsonASAnalysis of" exact="hepatitis" post="B viral load decline under potent therapy: complex decay"/>
  <result pre="therapy: complex decay profiles observedHepatology2001341012102010.1053/jhep.2001.2850911679973 20.DahariHShudoERibeiroRMPerelsonASModeling complex decay profiles of" exact="hepatitis" post="B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling amantadine treatment of"/>
  <result pre="hepatitis B virus during antiviral therapyHepatology200949323810.1002/hep.2258619065674 21.BeaucheminCAAMcSharryJJDrusanoGLNguyenJTWentGTRibeiroRMPerelsonASModeling amantadine treatment of" exact="influenza" post="A virus in vitroJ Theor Biol200825443945110.1016/j.jtbi.2008.05.03118653201 22.DobrovolnyHMGieschkeRDaviesBEJumbeNLBeaucheminCAANeuraminidase inhibitors for"/>
  <result pre="reservoir, and viral blipsJ Theor Biol200926030833110.1016/j.jtbi.2009.06.01119539630 26.GuedjJRongLDahariHPerelsonASA perspective on modelling" exact="hepatitis" post="C virus infectionJ Viral Hepat20101782583310.1111/j.1365-2893.2010.01348.x20723038 27.ChatterjeeAGuedjJPerelsonASMathematical modelling of HCV"/>
  <result pre="to evaluate interactions between drugsBiochem Pharmacol19965163564410.1016/S0006-2952(95)02230-98615900 37.DahariHRibeiroRMRiceCMPerelsonASMathematical modeling of subgenomic" exact="hepatitis" post="C virus replication in Huh-7 cellsJ Virol20078175076010.1128/JVI.01304-0617035310 38.McLeanAKLucianiFTanakaMMTrade-offs in"/>
  <result pre="Virol20078175076010.1128/JVI.01304-0617035310 38.McLeanAKLucianiFTanakaMMTrade-offs in resource allocation in the intracellular life-cycle of" exact="hepatitis" post="C virusJ Theor Biol201026756557210.1016/j.jtbi.2010.09.03120883700 39.NakabayashiJA compartmentalization model of hepatitis"/>
  <result pre="of hepatitis C virusJ Theor Biol201026756557210.1016/j.jtbi.2010.09.03120883700 39.NakabayashiJA compartmentalization model of" exact="hepatitis" post="C virus replication: an appropriate distribution of HCV RNA"/>
  <result pre="Theor Biol201230011011710.1016/j.jtbi.2012.01.02322286015 40.BinderMSulaimanovNClausznitzerDSchulzeMHüberCMLenzSMSchlöderJPTripplerMBartenschlagerRLohmannVKaderaliLReplication vesicles are load- and choke-points in the" exact="hepatitis" post="C virus lifecyclePLoS Pathog20139e100356110.1371/journal.ppat.100356123990783 41.JonkerDMVisserSAvan der GraafPHVoskuylRADanhofMTowards a mechanism-based"/>
  <result pre="sum of the partsDrug Discov Today200712344210.1016/j.drudis.2006.11.00817198971 46.KirouacDCDuJYLahdenrantaJOverlandRYararDParagasVPaceEMcDonaghCFNielsenUBOnsumMDComputational modeling of ERBB2-amplified" exact="breast cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
  <result pre="of the partsDrug Discov Today200712344210.1016/j.drudis.2006.11.00817198971 46.KirouacDCDuJYLahdenrantaJOverlandRYararDParagasVPaceEMcDonaghCFNielsenUBOnsumMDComputational modeling of ERBB2-amplified breast" exact="cancer" post="identifies combined ErbB2/3 blockade as superior to the combination"/>
  <result pre="and regulation relevant to Hepatitis C replicationMol Syst Biol2010637510.1038/msb.2010.3220531405 50.GuedjJPerelsonASSecond-phase" exact="hepatitis" post="C virus RNA decline during telaprevir-based therapy increases with"/>
  <result pre="therapy increases with drug effectiveness: implications for treatment durationHepatology2011531801180810.1002/hep.2427221384401 51.GuedjJNeumannAUUnderstanding" exact="hepatitis" post="C viral dynamics with direct-acting antiviral agents due to"/>
  <result pre="modes of action and yields a shorter estimate of the" exact="hepatitis" post="C virus half-lifeProc Natl Acad Sci U S A20131103991399610.1073/pnas.120311011023431163"/>
  <result pre="virus half-lifeProc Natl Acad Sci U S A20131103991399610.1073/pnas.120311011023431163 53.RongLGuedjJDahariHCoffieldDJLeviMSmithPPerelsonASAnalysis of" exact="hepatitis" post="C virus decline during treatment with the protease inhibitor"/>
  <result pre="multiscale modelPLoS Comput Biol20139e100295910.1371/journal.pcbi.100295923516348 54.RongLPerelsonASMathematical analysis of multiscale models for" exact="hepatitis" post="C virus dynamics under therapy with direct-acting antiviral agentsMath"/>
  <result pre="antiviral agentsMath Biosci2013245223010.1016/j.mbs.2013.04.01223684949 55.RongLDahariHRibeiroRMPerelsonASRapid emergence of protease inhibitor resistance in" exact="hepatitis" post="C virusSci Transl Med2010230ra3210.1126/scitranslmed.300054420445200"/>
 </snippets>
</snippetsTree>
